

Agilus Diagnostics launches new Anti-MCV antibody test for early diagnosis of rheumatoid arthritis

15 July 2025 | News

Anti-MCV test detects autoantibodies against a mutated form of the vimentin protein

Agilus Diagnostics, in collaboration with Sebia, has launched the cutting-edge Anti-MCV (anti-mutated citrullinated vimentin) antibody test in India. This advanced test significantly enhances the early detection of rheumatoid arthritis (RA), especially in patients who test negative for conventional markers like anti-CCP (cyclic citrullinated peptides) and rheumatoid factor (RF).

Rheumatoid arthritis (RA), one of the most common autoimmune disorders, affects approximately 0.5–1% of the Indian population, with prevalence expected to rise due to increased awareness and improved diagnostic capabilities .

A groundbreaking antibody test developed by Sebia, the anti-MCV (anti-mutated citrullinated vimentin) test, is redefining the early diagnosis and clinical management of rheumatoid arthritis (RA), especially in patients who remain undiagnosed using conventional methods.

The anti-MCV test detects autoantibodies against a mutated form of the vimentin protein, commonly found in the synovial fluid of patients with rheumatoid arthritis (RA). It has emerged as a highly sensitive and specific biomarker, particularly valuable for identifying RA in individuals who test negative for conventional markers such as anti-CCP and rheumatoid factor (RF). Studies have shown that anti-MCV can be positive even in the absence of traditional markers, especially in patients presenting with clinical signs and symptoms of RA. Furthermore, anti-MCV positivity may precede the clinical onset of RA by up to 24 months, particularly in individuals with a strong family history, making it a powerful tool for early detection and intervention.